Arterial hypertension and Aβ-amyloid accumulation have spatially overlapping effects on posterior white matter hyperintensity presence and volume

Importance Posterior white matter hyperintensities (WMH) in subjects across the Alzheimer's disease (AD) spectrum with minimal vascular pathology suggests that amyloid pathology ---not just arterial hypertension--- impacts WMH, adversely influencing cognition. Objective To characterise the effects of AD pathology, namely {beta}-amyloid (A{beta}) and hypertension on WMH and cognition. Design Cross-sectional and longitudinal Setting Multicentre Participants We analysed data from subjects with normal cognition (NC), subjective cognitive decline (SCD), and mild cognitive impairment (MCI) enrolled in the ongoing observational multicentre DZNE Longitudinal Cognitive Impairment and Dementia Study. We focused on participants with available magnetic resonance imaging (MRI), cerebrospinal fluid biomarkers, and cognitive and hypertension information. We conducted analyses between 02.2022 and 06.2022. Intervention(s) (for clinical trials) or Exposure(s) (for observational studies): NA Main Outcomes and Measures Spatial distribution and volume of MRI WMH in relation to A{beta}42/40 levels and arterial hypertension. Mediation of the relationship between A{beta} positivity and hypertension on cognition by the regional WMH volume. Results We included 355 participants (median age 70.3 [IQR 66.0-74.4] years; 168 female; 121 NC, 154 SCD, 80 MCI). Hypertension and A{beta} positivity were positively associated (p_FDR<0.05) with WMH volume, with large spatial overlap in the occipital lobes (regression coefficient {+/-} standard error; hypertension: 0.49 {+/-} 0.14; A{beta}: 0.41 {+/-} 0.15), parietal lobes (hypertension: 0.62 {+/-} 0.23; A{beta}: 0.61 {+/-} 0.24), corona radiata (hypertension: 0.55 {+/-} 0.19; A{beta}: 0.61 {+/-} 0.24), optic radiation (hypertension: 0.64 {+/-} 0.19; A{beta}: 0.50 {+/-} 0.20) and splenium (hypertension: 0.38 {+/-} 0.13; A{beta}: 0.39 {+/-} 0.13). Global and occipital WMH volumes were strongly associated cognitive changes over a three-year period, estimated with preclinical Alzheimer's cognitive composite 5 (PACC5) (global: 2.18 {+/-} 0.61, p_FDR<0.01; occipital: 3.31 {+/-} 0.75, p_FDR<0.01), regardless of A{beta} and hypertension status. The association between A{beta} positivity and baseline cognitive performance (direct-memory: -0.42 {+/-} 0.08, p_FDR<0.01; executive: -0.28 {+/-} 0.28, p_FDR<0.01) was partially mediated by WMH in the corona radiata (indirect-memory: -0.04 {+/-} 0.02, p_FDR<0.05; executive: -0.04 {+/-} 0.02, p_FDR<0.01) and splenium (indirect-memory: -0.02 {+/-} 0.02, p_FDR<0.01; executive: -0.04 {+/-} 0.02, p_FDR<0.01). Evidence supporting hypertension affected cognition was insufficient (direct-memory: 0.03 {+/-} 0.07, p_FDR=0.683; executive: -0.05 {+/-} 0.07, p_FDR=0.499; PACC5 change: 0.01 {+/-} 0.02, p_FDR=0.588). Conclusions and Relevance Posterior white matter is susceptible to vascular disease and A{beta} accumulation. Its deterioration is involved in the association between A{beta} and cognitive dysfunction. Posterior WMH could be a promising target to tackle the downstream damage related to the interacting and potentiating effect of these two pathologies. Trial Registration German Clinical Trials Register (DRKS00007966, 04/05/2015)

[1]  A. Spottke,et al.  Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  Nick C Fox,et al.  Associations of β-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort , 2022, Neurology.

[3]  Baoliang Zhong,et al.  Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality. , 2022, Journal of the American College of Cardiology.

[4]  V. Hachinski,et al.  White matter hyperintensities and longitudinal cognitive decline in cognitively normal populations and across diagnostic categories: A meta‐analysis, systematic review, and recommendations for future study harmonization , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[5]  M. Albert,et al.  Heart health meets cognitive health: evidence on the role of blood pressure , 2021, The Lancet Neurology.

[6]  G. Chételat,et al.  White matter hyperintensity topography in Alzheimer's disease and links to cognition , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  Farzaneh A. Sorond,et al.  Hypertension-induced cognitive impairment: from pathophysiology to public health , 2021, Nature Reviews Nephrology.

[8]  J. Hodges,et al.  Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease , 2021, Neurology.

[9]  Angela C. C. Jochems,et al.  Neuropsychiatric symptoms associated with cerebral small vessel disease: a systematic review and meta-analysis. , 2021, The lancet. Psychiatry.

[10]  G. Chételat,et al.  Topographic patterns of white matter hyperintensities are associated with multimodal neuroimaging biomarkers of Alzheimer’s disease , 2021, Alzheimer's research & therapy.

[11]  P. Selnes,et al.  Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns , 2020, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  F. Jessen,et al.  Minor neuropsychological deficits in patients with subjective cognitive decline. , 2020, Neurology.

[13]  J. Iliff,et al.  The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases. , 2020, International review of neurobiology.

[14]  Nick A. Weaver,et al.  Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions , 2019, Neurobiology of Aging.

[15]  M. Dichgans,et al.  Small vessel disease: mechanisms and clinical implications , 2019, The Lancet Neurology.

[16]  L. Beckett,et al.  White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities , 2019, Alzheimer's & dementia.

[17]  C. Jack,et al.  Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: the Mayo Clinic Study of Aging , 2019, Translational Psychiatry.

[18]  Paul Schmidt,et al.  LST: A lesion segmentation tool for SPM , 2019 .

[19]  Atul Narkhede,et al.  An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease , 2018, Neurology.

[20]  F. Jessen,et al.  Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE) , 2018, Alzheimer's Research & Therapy.

[21]  A. Evans,et al.  The vascular facet of late-onset Alzheimer's disease: an essential factor in a complex multifactorial disorder , 2017, Current opinion in neurology.

[22]  R. Sperling,et al.  Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5 , 2017, Alzheimer's & dementia.

[23]  Craig M. Hales,et al.  Hypertension Prevalence and Control Among Adults: United States, 2015-2016. , 2017, NCHS data brief.

[24]  S. Greenberg,et al.  White matter hyperintensity patterns in cerebral amyloid angiopathy and hypertensive arteriopathy , 2016, Neurology.

[25]  Liang-Jun Yan,et al.  Cerebral small vessel disease and Alzheimer’s disease , 2015, Clinical interventions in aging.

[26]  John T. O’Brien,et al.  This Work Is Licensed under a Creative Commons Attribution 4.0 International License Cortical Tau Load Is Associated with White Matter Hyperintensities , 2022 .

[27]  Paul M. Thompson,et al.  Fast and accurate modelling of longitudinal and repeated measures neuroimaging data , 2014, NeuroImage.

[28]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[29]  Evan Fletcher,et al.  Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study , 2012, The Lancet Neurology.

[30]  Karl J. Friston,et al.  Diffeomorphic registration using geodesic shooting and Gauss–Newton optimisation , 2011, NeuroImage.

[31]  J. Hatazawa,et al.  Blood pressure lowering with valsartan is associated with maintenance of cerebral blood flow and cerebral perfusion reserve in hypertensive patients with cerebral small vessel disease. , 2010, Journal of Stroke & Cerebrovascular Diseases.

[32]  D. Harvey,et al.  Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD , 2006, Neurology.

[33]  Elisabet Englund,et al.  Neuropathology of White Matter Changes in Alzheimer’s Disease and Vascular Dementia , 1998, Dementia and Geriatric Cognitive Disorders.

[34]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[35]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.